Timeline - COVID-19 Model and Validation
14 January 2020
WHO's technical lead for the response announced there may have been human-to-human transmission of the coronavirus (in the 41 confirmed cases), mainly through family members, and that there was a risk of a possible wider outbreak.
20 March 2020
Demiurge announced Pre-publication of the detailed aetiology and treatment rationale for critically ill COVID-19 patients.
23 February 2020
Demiurge announced prediction of the clinical benefits and risks and Remdesivir, Chloroquine, and PI3K inhibitors. (news)
30 April 2020
Real world data validated Demiurge clinical predication of remedesivir-specific post-treatment viral rebound in severely ill covid-19 patients. (news)
18 June 2020
Demiurge started publishing COVID-19 clinical trial prediction on twitter. (tweet)
03 April 2020
Real world data validated Demiurge clinical predication that ACE2 expression could be a predictive biomarker of COVID-19 mortality rate. (news)
14 February 2020
Demiurge's board approved the non-profit dissemination of our COVID-19 discoveries to speed up cross-border concerted efforts to develop COVID-19 therapeutics, and announced PI3K inhibitors as an AI discovered novel candidate treatment selective for COVID-19. (news)
07 March 2020
Demiurge announced AI Discovered the Complete Aetiology of COVID-19 and the optimal treatment strategy including ACE2 as a biomarker. (news)
01 April 2020
Real world data validated Demiurge Pathology-based AI Prediction of Persistent Infection of SARS-CoV-2 (news)
21 April 2020
Medical Hypotheses reviewed and accepted Demiurge AI Discovered the Complete Aetiology of COVID-19 and the Optimal Treatment Strategy for publication (paper)
7 May 2020
Demiurge announced prediction that the SARS-CoV-2 mutations converge upon pathways that functionally enhance covid-19 severity especially against the young for the long term. The diverse mutations of SARS-CoV-2 converge upon compensatory mechanisms that lead to longer viral sheddings, higher peak viral loads, worse clinical progressions, severer hematological complications, faster mutation rates, accelerated host aging, and more persistent infections.(here)
Since the outbreak of COVID-19, Demiurge has published 50+ COVID-19 phase 2 and phase 3 clinical trial prospective prediction and 41 of them have clinical readout. Demiurge's prediction accuracy is 85.4% (35/41).